Nuvation Bio Inc.

DB:1E30 Stock Report

Market Cap: €1.7b

Nuvation Bio Management

Management criteria checks 2/4

Nuvation Bio's CEO is David Hung, appointed in Apr 2018, has a tenure of 8.25 years. total yearly compensation is $3.88M, comprised of 16.8% salary and 83.2% bonuses, including company stock and options. directly owns 17.31% of the company’s shares, worth €300.41M. The average tenure of the management team and the board of directors is 4 years and 3.1 years respectively.

Key information

David Hung

Chief executive officer

US$3.9m

Total compensation

CEO salary percentage16.77%
CEO tenure8.3yrs
CEO ownership17.3%
Management average tenure4yrs
Board average tenure3.1yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has David Hung's remuneration changed compared to Nuvation Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$146m

Dec 31 2025US$4mUS$650k

-US$205m

Sep 30 2025n/an/a

-US$217m

Jun 30 2025n/an/a

-US$203m

Mar 31 2025n/an/a

-US$606m

Dec 31 2024US$4mUS$610k

-US$568m

Sep 30 2024n/an/a

-US$532m

Jun 30 2024n/an/a

-US$511m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$4mUS$593k

-US$76m

Sep 30 2023n/an/a

-US$83m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$8mUS$570k

-US$104m

Sep 30 2022n/an/a

-US$108m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$88m

Dec 31 2021US$5mUS$550k

-US$87m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$1mUS$475k

-US$42m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$33m

Dec 31 2019US$364kUS$218k

-US$34m

Compensation vs Market: David's total compensation ($USD3.88M) is above average for companies of similar size in the German market ($USD1.81M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Hung (68 yo)

8.3yrs
Tenure
US$3,876,736
Compensation

Dr. David T. Hung, M.D., serves as Founder, President, Chief Executive Officer and Director at Nuvation Bio Inc since April 2018 and has been it's Chairman of the Board since September 03, 2024. He founded...

Leadership Team

NamePositionTenureCompensationOwnership
David Hung
Founder8.3yrsUS$3.88m17.31%
€ 300.4m
Philippe Sauvage
CFO & Principal Financial Officer1.8yrsUS$1.48m0.0036%
€ 63.2k
Gary Hattersley
Chief Scientific Officer7.1yrsUS$1.47mno data
Moses Makunje
VP of Finance and Principal Accounting & Financial Officer2.7yrsno data0.0050%
€ 86.6k
David Hanley
Chief Technical Operations Officerno dataUS$3.31m0.0069%
€ 119.6k
Robert DeVita
Vice President of Corporate Development & Investor Relationsno datano datano data
Stephen Dang
Chief Legal Officer & Corporate Secretaryno datano datano data
Stacy Markel
Chief People Officer6.8yrsno data0.0094%
€ 162.4k
Kerry Wentworth
Chief Regulatory Officer4yrsno data0.015%
€ 264.1k
David Liu
Chief Medical Officer4yrsUS$1.34mno data
Colleen Sjogren
Chief Commercial Officer2.3yrsUS$2.28m0.024%
€ 418.5k
4.0yrs
Average Tenure
56yo
Average Age

Experienced Management: 1E30's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hung
Founder8.3yrsUS$3.88m17.31%
€ 300.4m
Kathryn Falberg
Independent Director5.8yrsUS$445.00k0.072%
€ 1.2m
Kim Blickenstaff
Independent Director6.9yrsUS$436.25k0.049%
€ 858.1k
Robert Bazemore
Lead Independent Director6yrsUS$483.00k0.0014%
€ 25.0k
Robert Mashal
Independent Director2.5yrsUS$422.50k0.065%
€ 1.1m
Gordon Mills
Member of Scientific Advisory Board3.1yrsno datano data
William Vernon
Independent Director7.1yrsUS$446.00k0.087%
€ 1.5m
Joyce O'Shaughnessy
Member of Scientific Advisory Board3.1yrsno datano data
Mansoor Mirza
Member of Scientific Advisory Board3.1yrsno datano data
Allyson Ocean
Member of Scientific Advisory Board3.1yrsno datano data
Johann de Bono
Member of Scientific Advisory Board3.1yrsno datano data
Wassim Abida
Member of Scientific Advisory Board3.1yrsno datano data
3.1yrs
Average Tenure
65.5yo
Average Age

Experienced Board: 1E30's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 12:26
End of Day Share Price 2026/07/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvation Bio Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Clarence PowellBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Silvan TuerkcanCitizens JMP Securities, LLC